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CASE REPORTPrimary cutaneous anaplastic large cell lymphoma
in a patient receiving adalimumab
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TNF: tumor necrosis factorINTRODUCTION
Antietumor necrosis factor (TNF) agents, such
as etanercept, infliximab, and adalimumab, are
increasingly used in the treatment of many
chronic inflammatory diseases, including psoriasis,
rheumatoid arthritis (RA), ankylosing spondylitis,
psoriatic arthritis, and inflammatory bowel disease.1
Because of their profound immunoregulatory effect,
antieTNF-a agents have long been suspected to
increase the risk of certain types of lymphomas,
although this has never been definitively proven. To
date, data from several studies and case reports have
shown an increased incidence of lymphoma in
patients treated with anti-TNF agents,1-4 although
other reports have failed to confirm or even refute
these findings. The studies lacked statistical power to
quantify the incidence of a rare disease after a rare
exposure. Adalimumab is a monoclonal antibody
against TNF-alfa (TNF-a) and is approved for use in
medical and dermatologic practice. We report a case
of primary cutaneous anaplastic large cell lymphoma
(PCALCL) in a patient with ankylosing spondylitis
and rheumatoid arthritis treated with adalimumab.CASE REPORT
A 72-year-old woman presented to a dermatology
clinic with a lesion located in the right medial lower
forehead region. The lesion began as a small
reddened area and after 1 week became a 2-cm
raised, dark black, circular mass lesion (Fig 1). No
lymphadenopathy was appreciated on physical
examination. The patient had ankylosing spondylitis
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noncontributory. A 5-mm punch biopsy specimen of
skin was obtained and sent for pathology.
The skin biopsy specimen showed ulceration
and loss of the epidermis, and the dermis was
completely replaced by an infiltrate of large atypical
mononuclear cells. These cells had ample
cytoplasm, irregular nuclei, vesicular chromatin,
and prominent nucleoli. Some nuclei appeared
reniform. Mitotic figures were easily seen. The tumor
cells were in sheets with interposed areas of
necrosis and hemorrhage. The lesion contained
neutrophils with scattered lymphocytes, eosinophils,
and histiocytes. Lymphoid germinal centers, gland
formation, and keratinization were not present
(Figs 2 and 3).
The neoplastic cells were diffusely positive for
CD3, CD4, CD30 (Fig 4), and vimentin. The
neoplastic cells did not express CD1a, CD8, CD20,
CD56, CD79a, anaplastic lymphoma kinase (ALK) 1,
PAX5, S100, tyrosinase, and cytokeratin AE1/AE3.
The positron emission tomography/computed
tomography scan showed a focal 1.1-cm soft
tissue nodule in the skin of the right foreheadJAAD Case Reports 2015;1:56-9.
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Fig 3. High-power magnification of PCALCL. (Hematoxylin-
eosin stain; original magnification: 3400.) A high-resolution
version of this slide for use with the Virtual Microscope is
available as eSlide: VM00490.
Fig 4. CD30 positivity in PCALCL. (CD30 immunostain;
original magnification:3200.) A high-resolution version of
this slide for use with the Virtual Microscope is available as
eSlide: VM00489.
Fig 1. Clinical photograph of lesion.
Fig 2. Low-powermagnificationof PCALCL. (Hematoxylin-
eosin stain; original magnification:3100.) A high-resolution
version of this slide for use with the Virtual Microscope is
available as eSlide: VM00490.
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The lesion had a maximum standardized uptake
value of 20 (liver maximum standardized uptake
value of 6.2). No destructive osseous lesion
was noted adjacent to the skin nodule. No other
abnormal subcutaneous 18F fluorodeoxyglucose up-
take was identified, and there was no evidence for
metastatic disease. Adalimumab was discontinued,
and the lesion was treated with electron beam
radiotherapy resulting in complete resolution. The
patient had no evidence of disease 19 months after
radiotherapy.
DISCUSSION
Primary cutaneous CD30-positive lymphoproli-
ferative disorders include PCALCL, lymphomatoid
papulosis (LyP), and borderline cases. PCALCL is a
neoplasm composed of large atypical lymphocytes
of either pleomorphic, anaplastic, or immunoblastic
cytomorphology and expression of the CD30 antigen
by more than 75% of tumor cells.5 It is the second
most common form of cutaneous T-cell lymphoma
(CTCL) with an incidence of 0.1 to 0.2 patients per
100,000.6 CTCL mainly affects people in their sixth
decade with a male to female ratio of 2 to 3:1.6The most common sites of involvement are the
extremities, head, and buttocks.5
Anaplastic large cell lymphoma (ALCL) usually
presents as an asymptomatic, solitary firm nodule
that rapidly grows and often ulcerates.5,6
Approximately 20% of the patients have multifocal
disease. The skin lesions may show partial or
complete spontaneous regression. ALCL frequently
relapses in the skin. Extracutaneous dissemination
occurs in about 10% of the patients in which regional
lymph node involvement is the most common
manifestation.5,6
Histology shows diffuse, usually nonepidermo-
tropic infiltrates with cohesive sheets of large
CD30-positive tumor cells. Most commonly, the
tumor cells show round, oval, or irregularly shaped
nuclei, prominent eosinophilic nucleoli, and
abundant cytoplasm.5 Reactive lymphocytes are
often present at the periphery of the lesion. The
neoplastic cells show an activated CD41 T-cell
phenotype with variable loss of CD2, CD5, or CD3
and frequently express cytotoxic proteins.5,7 CD30 is
by definition expressed by most ([75%) of
the neoplastic cells.5 Most cases show clonal
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PCALCL expresses cutaneous lymphocyte antigen
but do not express epithelial membrane antigen
(EMA) or ALK.8 The prognosis is usually favorable
with a 10-year disease-related survival rate of
approximately 90%.6
The primary differential diagnosis for PCALCL
includes LyP and secondary cutaneous involvement
by systemic ALCL. LyP has overlapping histopatho-
logic and phenotypic features with PCALCL5;
therefore, the distinction must be made by clinical
appearance and course. Lyp generally is more
indolent than PCALCL and is less likely to involve
the face. A patient with PCALCL should not have
clinical evidence or history of mycosis fungoides. In
this setting, the diagnosis should be considered
transformation of mycosis fungoides to tumor stage.5
Systemic ALCL with cutaneous involvement is a
separate disease with different cytogenetics, clinical
features, and outcomes.9 Systemic ALCL typically
expresses EMA while PCALCL does not. ALK
expression is a characteristic feature of systemic
ALCL, whereas it is rarely if ever found in PCALCL.9
Lymphomas have been reported in patients
treated with antieTNF-a agents. TNF-a blockers
used to treat inflammatory disorders are believed to
reduce host immune responses to malignancy.
Although it has been difficult to prove definitively
an associated risk of malignancy, one report10
suggested several possible mechanisms. First, the
binding of TNF-a to the respective cell surface
receptors is found to inhibit the programmed cell
death (apoptosis) pathway as well as cell-mediated
immunity. This blockade may also suppress the type
1 cytokine-mediated inhibition of type 2 CTCL or
CD301 lymphoma cells, thus, enabling more rapid
growth.10
There are very few individually reported cases of
several types of lymphoma in patients treated with
adalimumab. These include Hodgkin’s lymphoma,11
adult T-cell leukemia/lymphoma,12 hepatosplenic
T-cell lymphoma,4 and Epstein Barr viruse
associated plasmablastic lymphoma.2 One report of
LyP in a patient treated with adalimumab was
found.1
Meta-analysis by Wong et al3 detected that 11
(11/5,179; 0.21%) patients receiving antieTNF-a
therapy developed lymphomas. The adjusted overall
rates were 0.36 lymphomas per 1,000 person-years in
patients who did not receive antieTNF-a therapy
versus 1.65 lymphomas per 1,000 person-years in
patients who received antieTNF-a therapy. There
was a suggestion of increased lymphomas in the
treated group, with the predominant subset being
B-cell lymphomas. In their analysis, the occurrenceof lymphoma was rare and did not reach statistical
significance.3
Systematic review of the literature regarding the
safety of disease-modifying antirheumatic drugs by
Ramiro et al13 found that patients on TNF inhibitors
compared with patients on conventional drugs had a
higher risk of serious infections, a higher risk of
tuberculosis, and possibly an increased risk of
infection by herpes zoster. Patients on TNF inhibitors
did not have an increased risk for malignancies in
general, lymphoma, or nonmelanoma skin cancer,
but the risk of melanoma may be slightly increased.
Burmester et al14 reported that overall malignancy
rates for adalimumab-treated patients were as
expected for the general population; the incidence
of lymphoma was increased in patients with RA, but
within the range expected in RA without anti-TNF
therapy; nonmelanoma skin cancer incidence was
increased in RA, psoriasis, and Crohn’s disease.
Meta-analysis of cancer risks of anti-TNF agents by
Moulis et al15 did not find any evidence for an excess
cancer risk on TNF-a antagonists in adult rheumatoid
arthritis patients, but an excess cancer risk after
several years of exposure cannot be ruled out.
The risk of lymphoma is increased in patients
with RA, and spontaneous reporting suggests
that methotrexate and anti-TNF therapy might be
associated independently with an increased risk of
lymphoma. Although the risk is greatest for anti-TNF
therapies, differences between therapies are slight,
and confidence intervals for treatment groups
overlap. The increased lymphoma rates observed
with anti-TNF therapy may reflect channeling bias,
whereby patients with the highest risk of lymphoma
preferentially receive anti-TNF therapy. Current data
are insufficient to establish a causal relationship
between RA treatments and the development of
lymphoma.16
Deepak et al4 observed that the reported risk of
T-cell non-Hodgkin’s lymphomas was higher with
TNF-a inhibitor use in combinationwith thiopurines.
We report an unusual case of a PCALCL in a
patient receiving adalimumab. Like the reports from
these previous cases, we suggest TNF-a blockers
should be used carefully, and the adverse events
should be reported in detail.REFERENCES
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